Things are changing quickly in the Alzheimer’s space. Biomarkers can approximate the degree of amyloid build-up in the brain and there are two new FDA-approved medications that reduce that amyloid buildup and modestly slow down the progression of the disease. This GeriPal podcast discusses the topic of what primary care needs to manage this new world of Alzheimer’s disease effectively with Nathaniel Chin a geriatrician and clinician-scientist at the University of Wisconsin. Some of the specific areas covered include the following:
Has anything changed for the primary care doctor when diagnosing Alzheimer’s, how should we screen for cognitive impairment, what’s the role of assessing function, what do we do with those who have only subjective cognitive complaints, and what is the role of the amyloid antibody treatments?
Link: GeriPal Podcasts (02/2025)
